CDMO

Technology

Last mentioned: Feb 26, 2026

Stories mentioning CDMO 2

pharma Neutral

Agilent Q1 2026: Pharma Resilience Battles Academic Funding Headwinds

Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.

2 sources
market-trends Neutral

Agilent Navigates Tariff Headwinds and Academic Softness in Q1 2026

Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.

2 sources